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Rationale: Several predictors of mortality in patients with idiopathic
pulmonaryfibrosishavebeendescribed; however, there is aneed for
a practical and accurate method of quantifying the prognosis of in-
dividual patients.
Objectives: Develop a practical mortality risk scoring system for
patients with idiopathic pulmonary fibrosis.
Methods: We used a Cox proportional hazards model and data from
two clinical trials (n ¼ 1,099) to identify independent predictors of
1-yearmortality among patients with idiopathic pulmonary fibrosis.
From the comprehensivemodel, an abbreviated clinicalmodel com-
prised of only those predictors that are readily and reliably ascer-
tained by clinicians was derived. Beta coefficients for each predictor
were then used to develop a practical mortality risk scoring system.
Measurements and Main Results: Independent predictors of mortality
includedage, respiratoryhospitalization, percentpredictedFVC,24-
week change in FVC, percent predicted carbon monoxide diffusing
capacity, 24-week change in percent predicted carbon monoxide
diffusing capacity, and 24-week change in health-related quality of
life. An abbreviated clinical model comprising only four predictors
(age, respiratory hospitalization, percent predicted FVC, and 24-wk
change in FVC), and the corresponding risk scoring system pro-
duced estimates of 1-year mortality risk consistent with observed
data (9.9% vs. 9.7%; C statistic ¼ 0.75; 95% confidence interval,
0.71–0.79).
Conclusions: The prognosis for patients with idiopathic pulmonary
fibrosis may be accurately determined using four readily ascertain-
ablepredictors.Our simplified scoring systemmaybea valuable tool
for determining prognosis and guiding clinical management. Addi-
tional research is needed to validate the applicability andaccuracyof
the scoring system.
Keywords: interstitial lung disease; risk factors; vital capacity; mortality
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-
threatening, interstitial lung disease of unknown etiology (1).
Respiratory failure resulting from IPF is the most frequent
cause of death, and has been reported to account for over
80% of all fatalities (2, 3). Heart failure, bronchogenic carci-
noma, ischemic heart disease, infection, and pulmonary embo-
lism are also causes of mortality in IPF (3).
Although median survival among patients with IPF is only 2
to 3 years, some patients live much longer. Several studies have
focused on identifying predictors of mortality in patients with
IPF, including those based on data obtained at a single point
in time (baseline predictors), and those based on data obtained
over time (longitudinal predictors) (1, 4–18). Research pub-
lished to date, however, has been limited in one or more facets
of study design or study population, including retrospective data
collection, small sample size, or use of a putative predictor that
is not commonly assessed in clinical practice. Moreover, pre-
sumably because of these limitations, research in this area has
failed to yield a scoring system that is routinely used in clinical
practice to predict individual risk of mortality (4, 5). Develop-
ment of such a scoring system is important, because it may serve
as a basis for clinical decision making and simplify clinical trial
design.
Using data from two large clinical trials in patients with IPF,
we undertook a study to identify independent predictors of mor-
tality and, based on these findings, develop a risk scoring system
that once validated could be used by clinicians in daily practice
without the need for sophisticatedmeasures of disease status that
are available only in specialized centers. This work has been pre-
sented in part at the 2010 international meeting of the American
Thoracic Society (19).
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Several studies have identified independent predictors of
mortality in patients with idiopathic pulmonary fibrosis.
Research published to date, however, has failed to yield
a scoring system to predict individual risk of mortality.
What This Study Adds to the Field
Our findings suggest that a practical risk scoring system
based on four readily and reliably ascertainable predictors
may be used to accurately assess the risk of 1-year mortality
in individual patients with idiopathic pulmonary fibrosis and
thereby facilitate clinical decision making. Validation of the
risk scoring system in other populations of patients with
idiopathic pulmonary fibrosis is needed.
METHODS
Source and Study Populations
The source population consisted of all randomized patients (n¼ 1,156) in
two clinical trials of IFN-g1b (protocols GIPF-001 [n ¼ 330] and GIPF-
007 [n ¼ 826]) irrespective of treatment assignment (placebo [n¼ 443] or
IFN-g1b [n ¼ 713]). The designs of these trials are described in detail
elsewhere (2, 20). Briefly, eligible patients were required to have a high-
resolution computed tomography scan showing features consistent with
protocol-defined criteria for either a definite or probable diagnosis of
IPF. Surgical lung biopsy was required to confirm a diagnosis in all
patients with a clinical and radiographic diagnosis of probable IPF, and
all patients under the age of 50 years, regardless of the degree of certainty
associated with the clinical and radiographic diagnoses.
From the source population, we selected for inclusion all patients
(n ¼ 1,099) who participated in the week-24 trial visit (data from the
week-24 visit were required to characterize changes from baseline in
longitudinal predictors) (Figure 1). Patients who died or had a lung
transplant between baseline and the week-24 visit (n ¼ 39), or who
were lost to follow-up during this period (n ¼ 18), were therefore
excluded from the analyses.
Predictors of Mortality
Potential predictors of mortality were assessed during the period from the
trial baseline to the week-24 trial visit, and during the period from the
week-48 to the week-72 trial visits, respectively, and all deaths occurring
over the 48-week periods after these periods were identified. Specifically,
a recordwas created for each patient consisting of data on predictors from
the baseline and week-24 visits and, if observed, the week-48 and week-72
trial visits, respectively, and patients who died during the subsequent 48
weeks were flagged accordingly.All such recordswere pooled into a single
dataset for analysis; therefore, patients may have contributed up to two
unique observations to the study database.
Potential predictors were identified a priori based on biologic
plausibility and clinical rationale. Patient sex, race, smoking status,
history of cardiovascular disease, presence of honeycombing on high-
resolution computed tomography scans, use of supplemental oxygen,
and history of surgical lung biopsy were evaluated based on informa-
tion collected at the baseline visit. Age, body mass index, use of con-
comitant medications, percent predicted FVC, percent predicted
carbon monoxide diffusing capacity (DLCO), the University of Califor-
nia at San Diego Shortness of Breath Questionnaire (UCSD SOBQ),
and the St. George’s Respiratory Questionnaire (SGRQ) were evalu-
ated at the baseline and week-48 trial visits (for baseline data corre-
sponding to the week-24 and week-72 trial visits, respectively).
Longitudinal changes in measures of physiologic status, dyspnea
(assessed by the UCSD SOBQ), and health-related quality of life
(HRQL, assessed by the SGRQ), and the occurrence of respiratory
hospitalization, were evaluated over the 24-week periods immediately
preceding the week-24 and week-72 trial visits. Trial treatment assign-
ment (IFN-g1b vs. placebo), trial enrollment (GIPF-001 vs. GIPF-007),
and country of residence were included as possible confounders.
Statistical Analyses
Crude (unadjusted) risks of all-cause mortality (per person-year) were
estimated for patients stratified by each potential predictor separately,
as were corresponding (unadjusted) hazard ratios using Cox propor-
tional hazards models. To optimize model fit and aid in interpretation
of study results, potential predictors that are continuous in nature were
characterized using categorical variables, because such variables
exhibited in formal and informal tests a nonlinear relationship withmor-
tality. Thresholds separating categories for a given predictor were de-
fined initially based on the quintiles of their distributions; some
thresholds were subsequently modified based on distributional proper-
ties of the empirical data and thresholds previously used in published
clinical research (see Table E1 in the online supplement).
A multivariate Cox proportional hazards model was estimated to
identify independent predictors of all-cause mortality. All dichotomous
measures with P values less than 0.10 in unadjusted analyses were
initially included in the model; grouped dichotomous variables were
included if any of the grouped variables had a P value less than 0.10.
We subsequently excluded from this model all variables that were no
longer important predictors in a multivariate context. The robustness
of the final specification to alternative approaches for eliminating var-
iables from the model was evaluated.
From the fully specified model, an abbreviated clinical model com-
prised only of predictors that are readily and reliably evaluable by clini-
cians and that might be used to assess patient risk in clinical practice was
also estimated. The importance of interactions between all levels of se-
lected predictors, along with the selected predictors, was evaluated by
the stepAIC method using backward and forward selection.
Only observed data were used (i.e., missing values were not im-
puted); therefore, the size of the study population may be slightly dif-
ferent across analyses, as noted. Subjects who underwent lung transplant
(n ¼ 28) during follow-up were censored on the corresponding date.
The presence of multicollinearity, hazards assumptions, and model dis-
crimination were evaluated using published methods (21, 22). Model
discrimination was quantified based on the C statistic, which is the
probability that among two randomly selected patients the patient with
the higher predicted risk of an event will be the first to experience the
event. The C statistic ranges from 0.5 (model discrimination is no
better than chance) to 1 (model discrimination is perfect). A C statistic
between 0.70 and 0.80 is typically considered “acceptable,” whereas
a value exceeding 0.80 is typically considered “excellent.”
Figure 1. Schematic of study design.
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A mortality risk scoring system was developed using methodology
set forth by Wilson and coworkers (23) and used in other studies (24,
25). Specifically, b coefficients from the abbreviated Cox model were
converted to scores by multiplying each by 10 and rounding to the
nearest integer. A mortality risk score was calculated for each study
subject by summing the individual scores corresponding to his or her
characteristics; the baseline hazard function from the Cox model was
then used to convert the total risk score to a 1-year probability of death
as follows: p(death) ¼ 1 – 0.988exp[0.1*total risk score], where 0.988 is the
estimated 1-year probability of survival, and thus 1 – 0.988 is the esti-
mated 1-year probability of death for persons with the lowest risk
(i.e., those with a total risk score equal to 0). To verify that estimates
of risk produced by the scoring system were consistent with observed
data, subjects were stratified into quintiles based on their risk scores,
and average risks calculated from the scoring system were compared
with observed risks (using the Kaplan-Meier method). Calibration and
discrimination were evaluated using the chi-square statistic and C sta-
tistic, respectively.
RESULTS
Patient Characteristics
Among the 1,156 patients with IPF who were enrolled in the two
clinical trials of IFN-g1b, 1,099 participated in the week-24 trial
visit and thus qualified for inclusion in the study population
(Table 1). Mean age was 65 (SD ¼ 8) years, 70% were male,
and 75% were United States residents. Mean baseline percent
predicted FVC was 68 (SD ¼ 14), and percent predicted DLCO
was 42 (SD ¼ 12). Among the 1,099 patients, 830 participated in
the week-72 visit; thus, the study database included a total of
1,929 patient-visits.
Predictors of Mortality
There were a total of 152 deaths; 98 deaths occurred between the
week-24 and week-72 trial visits (mean duration of follow-up,
43 wk), whereas the remainder (n ¼ 54) occurred during the
48-week period after the week-72 trial visit (mean duration of
follow-up, 29 wk). Crude 1-year risk of mortality was 9.7%
(95% confidence interval [CI], 8.2–11.2). Unadjusted risks of
mortality were systematically different (P , 0.10) across one
or more strata for the following variables: age; supplemental
oxygen use; history of surgical lung biopsy; 24-week history
of respiratory hospitalization; prednisone use; azathioprine
use; percent predicted FVC; 24-week change in percent pre-
dicted FVC; percent predicted DLCO; 24-week change in per-
cent predicted DLCO; dyspnea score (assessed by UCSD
SOBQ); 24-week change in dyspnea score; HRQL (assessed
by SGRQ); and 24-week change in HRQL (Table 2).
In the multivariate model, statistically significant independent
predictors of all-cause mortality included age, history of respira-
tory hospitalization, percent predicted FVC, 24-week change in
percent predicted FVC, percent predicted DLCO, 24-week change
in percent predicted DLCO, and 24-week change in HRQL (Table
3). This comprehensive model was found to be robust across
alternative approaches for eliminating variables from the model,
with each yielding the same set of predictors. Model discrimina-
tion, based on the C statistic, was 0.77 (95% CI, 0.72–0.81).
From the comprehensive model, an abbreviated clinical
model including only those factors that are readily and reliably
evaluable in the typical clinical setting was derived. These in-
cluded age, 24-week history of respiratory hospitalization, per-
cent predicted FVC, and 24-week change in percent predicted
FVC (Table 3). Among these, the strongest independent pre-
dictor of mortality was the 24-week change in percent predicted
FVC. Of note, a 24-week change of 25% to 29.9% was asso-
ciated with a more than twofold increase in the risk of death
over the subsequent 12 months (hazard ratio [HR], 2.60 [95%
CI, 1.75–3.85; P , 0.001]), whereas a decline greater than or
equal to 10% was associated with an eightfold increase in the
risk of 1-year mortality (HR, 7.99 [95% CI, 5.26–12.14; P ,
0.001]). Model discrimination for the clinical model was 0.75
(95% CI, 0.71–0.79), indicating that the discriminatory power
was comparable with that of the comprehensive model. Multi-
collinearity between independent variables and nonpropor-
tional hazards were determined not to be significant in any of
the multivariate models, and results were robust across models
when focusing on the subset of patient visits (n ¼ 1,444) with
data available for all potential predictors. Consideration of in-
teraction terms in the clinical model selected by the stepAIC
method failed to improve model discrimination.
Mortality Risk Scoring System
A simplified mortality risk scoring system was developed based
on the b coefficients for each predictor in the abbreviated Cox
model. The mortality risk scoring system is presented in Table
4. Overall, the scoring system overestimated mortality risk by,
in relative terms, less than 2% (observed risk, 9.7% vs. esti-
mated risk from scoring system, 9.9%) (Table 5). The ratio
of risk from the scoring system to observed risk ranged from
0.65–1.13 across patient quintiles; absolute differences ranged
from 0.3–2%. Calibration (P value ¼ 0.316) and discrimination
(C statistic ¼ 0.75 [95% CI, 0.71–0.80]) of the scoring system
were good.
The expected 1-year risk of mortality for an individual patient
can be ascertained by summing the scores for each of the four
predictors and comparing the total score with the corresponding
expected 1-year risk of mortality (Table 4). For example, the
total score for a 66-year-old patient with a history of respiratory
hospitalization, a percent predicted FVC of 68%, and a 24-week
change in percent predicted FVC of less than25% is 26 (41 14
1 8 1 0), which corresponds to a 10–20% risk of 1-year mor-
tality. By contrast, the total score for a patient with the same
age, baseline FVC, and history of respiratory hospitalization,
yet with a 24-week change in percent predicted FVC between
25 and 29.9%, is 36 (4 1 14 1 8 1 10), which corresponds to
a 30–40% risk of 1-year mortality.
TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS WITH
IDIOPATHIC PULMONARY FIBROSIS
Characteristics N (%)
Demographic
Age, yr
,60 240 (21.8)
60–69 473 (43.1)
>70 386 (35.1)
Male 772 (70.2)
Race
White 1,013 (92.2)
Other 86 (7.8)
Country of residence
United States 826 (75.2)
Other 273 (24.8)
Clinical
Honeycombing on HRCT 947 (86.2)
Surgical lung biopsy 638 (58.1)
History of cardiovascular disease 299 (27.2)
Treatment assignment
Placebo 418 (38)
IFN-g1b 681 (62)
Study
GIPF-007 801 (72.9)
GIPF-001 298 (27.1)
Definition of abbreviation: HRCT ¼ high-resolution computed tomography.
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TABLE 2. UNADJUSTED ANALYSES OF PREDICTORS OF ALL-CAUSE MORTALITY AMONG PATIENTS WITH
IDIOPATHIC PULMONARY FIBROSIS
Covariates Subject Visits (n) Deaths (n) Deaths (%) HR 95% CI P Value
Demographic
Age
,60 417 22 5.3 0.51 0.32–0.83 0.006
60–69 817 59 7.2 0.71 0.50–1.00 0.053
>70 690 71 10.3 — — —
Sex
Male 1,347 113 8.4 1.23 0.86–1.77 0.262
Female 577 39 6.8 — — —
Race
White 1,775 139 7.8 0.95 0.54–1.69 0.865
Other 149 13 8.7 — — —
Country
United States 1,459 109 7.5 0.79 0.56–1.13 0.202
Other 465 43 9.2 — — —
Clinical
Current smoker
Yes 92 4 4.3 0.49 0.18–1.32 0.157
No 1,832 148 8.1 — — —
Oxygen use
Yes 485 58 12 1.85 1.34–2.57 ,0.001
No 1,431 94 6.6 — — —
Honeycombing on HRCT
Yes 1,652 132 8 1.07 0.67–1.71 0.790
No 271 20 7.4 — — —
Surgical lung biopsy
Yes 1,126 72 6.4 0.62 0.45–0.86 0.004
No 795 80 10.1 — — —
History of cardiovascular disease
Yes 520 41 7.9 1.00 0.70–1.43 0.991
No 1,404 111 7.9 — — —
History of respiratory hospitalization
Yes 77 26 33.8 6.22 4.07–9.49 ,0.001
No 1,847 126 6.8 — — —
Prednisone use
.10 mg per day 296 40 13.5 2.16 1.48–3.15 ,0.001
<10 mg per day 295 29 9.8 1.54 1.01–2.35 0.047
0 1,338 83 6.2 — — —
Azathioprine use
Yes 17 5 29.4 4.82 1.97–11.75 0.001
No 1,907 147 7.7 — — —
Physiologic
% Predicted FVC
<50 99 14 14.1 4.45 2.14–9.44 ,0.001
51–65 726 75 10.3 3.02 1.69–5.33 ,0.001
66–79 677 48 7.1 2.18 1.28–4.18 0.005
>80 412 14 3.4 — — —
24-Week change in % predicted FVC
< 210 166 39 23.5 7.06 4.21–11.84 ,0.001
25 to 29.9 373 45 12.1 3.43 2.07–5.66 ,0.001
0 to 24.9 678 34 5 1.37 0.81–2.33 0.237
.0 638 23 3.6 — — —
% Predicted DLco
<35 397 50 12.6 2.68 1.75–4.12 ,0.001
36–45 716 61 8.5 1.84 1.22–2.78 0.004
.45 772 36 4.7 — — —
24-Week change in % predicted DLco
< 215 103 18 17.5 4.61 2.53–8.38 ,0.001
214.9 to 210 124 15 12.1 2.86 1.52–5.39 0.001
29.9 to 0 938 62 6.6 1.56 0.99–2.44 0.056
.0 612 27 4.4 — — —
Dyspnea and HRQL
UCSD SOBQ
.80 97 14 14.4 3.37 1.74–6.51 ,0.001
61–80 249 24 9.6 1.89 1.07–3.33 0.029
41–60 433 41 9.5 1.99 1.20–3.30 0.007
21–40 576 46 8 1.62 0.99–2.65 0.057
<20 491 24 4.9 — — —
24-Week change in UCSD SOBQ
.10 490 71 14.5 2.73 1.96–3.82 ,0.001
(Continued )
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DISCUSSION
The clinical course of patients with mild to moderate IPF is
characterized by physiologic deterioration (as measured by
FVC, DLco, and alveolar–arterial oxygen gradient); worsening
severity of dyspnea; and frequent hospitalizations for respira-
tory disorders (3). Hospitalization for a respiratory condition is
a particularly ominous event, with up to half of the IPF-related
deaths occurring after such an event (3). In addition, although
most patients experience an insidious decline in lung function
that ultimately proves fatal, considerable intersubject and intra-
subject variability may be observed (3). As a result, formulating
an accurate prognosis for an individual patient with IPF repre-
sents a distinct clinical challenge. Two clinical prediction mod-
els have been developed for patients with IPF (4, 5). To date,
however, use of these prediction models and corresponding risk
scoring systems has been confined to clinical research, largely
based on the inclusion of factors that are not widely accessible
in the clinical setting or for which the measurement character-
istics preclude widespread clinical use.
In the present study, we identified significant predictors of
mortality among a well-defined cohort of patients with IPF
and developed a simplified scoring system that may be easily
used in clinical practice to assess the 1-year risk of mortality
for an individual patient. Development of the scoring system
was based on data from two of the largest clinical trials to date
in patients with IPF; the study population included more than
1,000 patients from the United States and Europe with a wide
range of demographic, clinical, and physiologic characteristics.
Additionally, although all patients had mild to moderate func-
tional impairment at baseline, many progressed during the pe-
riod of observation. Consequently, our scoring system should
be generalizable to the population of patients typically treated
in respiratory clinical practice. We note that because our objec-
tive was to use all available data to develop a robust risk scoring
system that is sensitive to the potential importance of relatively
small differences in variable values, we chose not to split our
sample for purposes of validation, and we were unable to vali-
date the risk scoring system using data from a different source.
Thus, whether the scoring system would perform comparably in
other populations of patients with IPF is currently unknown, and
validation using data from other large populations of patients
with IPF are therefore needed.
We included only four predictors in our scoring system, each of
which can be readily and reliably ascertained in the typical clinical
setting. These predictors included age, history of respiratory hos-
pitalization within the previous 24 weeks, percent predicted FVC,
and 24-week change in percent predicted FVC. Importantly, we
found that a decline in percent predicted FVC as small as 5%
at 6 months was associated with a more than twofold increase
in the risk of death over the subsequent 12 months. This finding
is particularly noteworthy because it highlights the prognostic sig-
nificance of changes in FVC that were previously regarded as
within the range of test variability and thus evidence of clinically
stable disease. Only one other study to date has reported a similar
finding regarding the predictive value of categorical changes in
FVC less than 10%. In a study that included 84 patients with
TABLE 2. (CONTINUED)
Covariates Subject Visits (n) Deaths (n) Deaths (%) HR 95% CI P Value
<10 1,255 68 5.4 — — —
SGRQ (summary)
>60 334 39 11.7 2.33 1.38–3.93 0.002
46–59 488 40 8.2 1.56 0.93–2.63 0.093
31–45 527 43 8.2 1.60 0.95–2.67 0.075
,30 413 22 5.3 — — —
24-Week change in SGRQ (summary)
.20 81 25 30.9 5.92 3.74–9.37 ,0.001
11–20 209 32 15.3 2.80 1.84–4.25 ,0.001
<10 1,242 71 5.7 — — —
Definition of abbreviations: CI ¼ confidence interval; DLco ¼ carbon monoxide diffusing capacity; HR ¼ hazard ratio; HRCT ¼
high-resolution computed tomography; HRQL ¼ health-related quality of life; SGRQ ¼ St. George’s Respiratory Questionnaire;
UCSD SOBQ ¼ University of California San Diego Shortness of Breath Questionnaire.
TABLE 3. MULTIVARIATE ANALYSES OF PREDICTORS OF
ALL-CAUSE MORTALITY AMONG PATIENTS WITH
IDIOPATHIC PULMONARY FIBROSIS
HR for Death
Comprehensive Model* Clinical Model†
HR 95% CI P Value HR 95% CI P Value
Age
>70 2.19 1.22–3.95 0.009 2.21 1.35–3.62 0.002
60–69 1.64 0.91–2.94 0.10 1.49 0.90–2.46 0.120
,60 1.00 — — 1.00 — —
History of respiratory hospitalization
Yes 2.82 1.61–4.97 ,0.001 4.11 2.57–6.58 ,0.001
% Predicted FVC
<50 3.90 1.49–10.19 0.006 5.79 2.55–13.15 ,0.001
51–65 2.35 1.18–4.78 0.016 3.54 1.95–6.44 ,0.001
66–79 1.46 0.73–2.92 0.291 2.20 1.19–4.09 0.012
>80 1.00 — — 1.00 — —
24-Week change in % predicted FVC
< 210 3.65 2.03–6.57 ,0.001 7.99 5.26–12.14 ,0.001
25 to 29.9 1.95 1.24–3.09 0.004 2.60 1.75–3.85 ,0.001
. 25 1.00 — — 1.00 — —
% Predicted DLco
<35 1.74 1.01–2.99 0.046
36–45 1.29 0.78–2.13 0.319
.45 1.00 — —
24-Week change in % predicted DLco
< 215 2.41 1.19–4.87 0.015
214.9 to 210 1.61 0.79–3.28 0.190
29.9 to 0 1.29 0.78–2.13 0.317
.0 1.00 — —
24-Week change in HRQL (SGRQ)
.20 3.63 2.08–6.34 ,0.001
11–20 1.59 0.98–2.58 0.058
<10 1.00 — —
Definition of abbreviations: CI ¼ confidence interval; DLco ¼ carbon monoxide
diffusing capacity; HRQL ¼ health-related quality of life; HR ¼ hazard ratio;
SGRQ ¼ St. George’s Respiratory Questionnaire.
* n (patient visits) ¼ 1,444, n (deaths) ¼ 110, C statistic (95% CI), 0.77
(0.72–0.81).
y n (patient visits) ¼ 1,854, n (deaths) ¼ 142, C statistic (95% CI), 0.75
(0.71–0.79).
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biopsy-proven IPF, Zappala and coworkers (18) observed a sig-
nificant increase in the risk of mortality among patients who
experienced a 5–10% decline in percent predicted FVC over 6
months (HR, 2.31 [95% CI, 1.19–4.50]). Although this study was
limited by a relatively small sample size and potential confound-
ing by a range of variables for which we controlled in our study,
the magnitude of the observed risk associated with a 5–10% de-
cline in FVC was strikingly similar to that of the present study
(HR, 2.60 [95% CI, 1.75–3.85]). The discriminative ability of our
mortality risk model compares favorably with others, including
predictive models for long-term survival after lung transplanta-
tion (26). These models, which considered selected pretransplant
demographic and clinical characteristics as potential predictors,
and separately, post-transplant parameters included in the Lung
Allocation System, performed poorly in predicting long-term sur-
vival, with C statistics for the various models all less than 0.60.
C statistics for several cardiovascular disease models based on
data from the Framingham Heart Study range from 0.66–0.79
(23, 27–30).
Consistent with prior research, we also found that baseline per-
cent predicted DLco was an important predictor of mortality (4, 5,
7, 8, 31, 32). However, we decided not to include DLco in the risk
scoring system because it exhibits considerable variability in clin-
ical practice and is not as widely available as the other measures
that were included in the abbreviated clinical model. Based on
these factors, we concluded that its inclusion would likely limit
the use of our scoring system among clinicians. Importantly, ex-
cluding baseline and longitudinal measures of percent predicted
DLco (and change in HRQL) had no meaningful impact on model
discrimination, suggesting that measures of DLco may not be in-
crementally informative in differentiating between patients with
IPF based on their mortality risk (Table 6).
Our findings have several potentially important implications
for both clinical practice and clinical trial design. First, although
there is considerable variability in prognosis among patients with
IPF, our data suggest that an IPF patient’s prognosis may be
readily and accurately assessed, and such information may be
used as a basis for management decisions that are significantly
informed by discussions with patients about the relative risks of
treatment against the risks of progressive disease. Additionally,
our findings may aid in the identification of appropriate candi-
dates for enrollment in clinical trials and facilitate accurate
stratification, both of which may contribute to a more efficient
and properly “powered” clinical trial.
Some limitations of our study are noteworthy. First, these
clinical trials enrolled a group of patients with mild to moderate
impairment of pulmonary function at baseline. The study did not
include patients who were too ill or considered at high risk for
dying during the course of the trial (2, 20). We acknowledge in
particular the exclusion of patients with severe emphysema,
because emerging evidence suggests that comorbid emphysema
may have a potentially important impact on survival and
TABLE 4. MORTALITY RISK SCORING SYSTEM FOR PATIENTS WITH IDIOPATHIC
PULMONARY FIBROSIS
(1) Sum individual scores corresponding to level
of each risk factor for a given patient*
(2) Find expected 1-year probability of death
corresponding to total risk score
Risk Factors Score Total Risk Score Expected 1-Year Risk of Death
Age
>70 8
60–69 4 0–4 ,2%
,60 0 8–14 2–5%
History of respiratory hospitalization 16–21 5–10%
Yes 14 22–29 10–20%
No 0 30–33 20–30%
% Predicted FVC 34–37 30–40%
<50 18 38–40 40–50%
51–65 13 41–43 50–60%
66–79 8 44–45 60–70%
>80 0 47–49 70–80%
24-Week change in % predicted FVC .50 .80%
< 210 21
25 to 29.9 10
. 24.9 0
* For example: total score for a patient aged 70 years, with no history of respiratory hospitalization, a % predicted FVC of 51–
65, and a 24-week change in % predicted FVC of 25 to 29.9, is 31 (8 1 0 1 13 1 10) and predicted 1-year probability of death,
20–30%.
TABLE 5. OBSERVED ONE-YEAR RISK OF DEATH AMONG
PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND
ESTIMATES FROM RISK SCORING SYSTEM
Risk Group
(score) N
Observed
Risk (%)
Risk from Scoring
System (%) Ratio*
All patients 1,854 9.7 9.9 1.02
Quintiles of patients, by risk score
1st (< 11) 368 3.4 2.2 0.65
2nd (12–15) 359 4.4 4.1 0.93
3rd (16–17) 361 5.4 6 1.12
4th (18–24) 384 9.3 9 0.96
5th (> 25) 382 25 27.1 1.08
* Observed risk versus risk from scoring system.
TABLE 6. ALTERNATIVE CLINICAL MODEL SPECIFICATIONS
Model Independent Variables C Statistic (95% CI)
Clinical model Age, respiratory hospitalization,
FVC, DFVC
0.75 (0.71–0.79)
Model B Age, respiratory hospitalization,
DLco, DDLco
0.70 (0.66–0.75)
Model C Age, respiratory hospitalization,
FVC, DLco
0.71 (0.66–0.75)
Model D Age, FVC, DLco, DFVC, DDLco 0.75 (0.71–0.80)
Model E Age, FVC, DLco 0.66 (0.62–0.70)
Definition of abbreviations: DDLco ¼ 24-week change in carbon monoxide
diffusing capacity; DFVC ¼ 24-week change in FVC; CI ¼ confidence interval;
DLco ¼ carbon monoxide diffusing capacity.
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longitudinal measures of pulmonary function in patients with
IPF. Although the trial populations undoubtedly included some
patients with mild to moderate emphysema, further assessment
of the prognostic significance of comorbid emphysema was not
possible and remains for future research. The generalizability of
study results (e.g., the importance of a 5–9% decline in FVC vis-
a`-vis mortality) and the applicability of the risk scoring system
to patients excluded from the trial populations are unknown.
Second, although the study database included a broad range of
demographic, clinical, and physiologic parameters for a large num-
ber of study subjects, potential predictors of mortality that have
been reported to be independently significant in several recent
small studies were not included in our analysis. Brain natriuretic
protein, a noninvasive marker for pulmonary hypertension, was
recently shown in one study to be a predictor of mortality in
patients with IPF (16). In another recent small study, CT visual
scores were found to be a useful predictor of mortality in IPF
(14). Additionally, 6-minute walk distance has been reported to
be an independent predictor of mortality in patients with IPF on
a waiting list for lung transplantation (10). More recently, both
baseline 6-minute walk distance and the change in 6-minute walk
distance at 12 months were identified as independent predictors
of mortality in a small cohort of patients with IPF (17). Whether
further research will establish these and possibly other measures
as important predictors of mortality in IPF and whether the ad-
dition of these predictors to our model would significantly en-
hance its predictive accuracy is unknown.
Third, although using categorical variables for continuous
measures is typically less desirable (vs. considering continuous
measures and corresponding higher-order effects), we did so
to aid in the interpretation and use of study results. Fourth, hos-
pitalizations were designated as respiratory in nature based on
assessments by principal investigators, and such designations
were not formally adjudicated. Finally, although our analyses
would have ideally been limited to patients randomized to pla-
cebo in the clinical trials, we concluded based on the absence of
evidence for any treatment effect that the enhanced power of the
study to identify independent predictors of mortality justified the
inclusion of all randomized patients.
In conclusion,we found that among a large andwell-characterized
population of patients with IPF several parameters were impor-
tant independent predictors ofmortality, including changes in per-
cent predicted FVC that were previously regarded as evidence of
clinically stable disease.We also found that an abbreviated clinical
model comprising four predictors that are readily and reliably as-
certainable in clinical practice performed well in discriminating
between patients with IPF based on their risk of death, and that
a risk scoring system based on these characteristics may be used to
accurately assess an individual patient’s risk of death and facilitate
clinical decision making. Additional research using data from
other large populations of patients with IPF is needed to validate
the applicability and accuracy of our scoring system.
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